In preclinical research on PDAC, inhibition of CXCR4 at both the pharmacological and genetic levels led to the rapid buildup of CD8+ T cells in tumors and a reduction in tumor growth (Feig et al., 2013). The gene discussed is CD8A; the disease is neoplasm.